Search Results 341-350 of 16006 for SC

  1. Selected Publications by Faculty and Fellows Source: Cho, J. Seville, MT. Khanna, S. Pardi, DS. Sampathkumar, P. Kashyap, PC. Sc

    Source: Cho, J. Seville, MT. Khanna, S. Pardi, DS. Sampathkumar, P. Kashyap, PC. Screening for. Clostridium difficile colonization on admission to a ...

  2. A Study to Evaluate the Effectiveness and Safety of Risankizumab in Subjects with Moderately-to-Severely Active Ulcerative Colitis - Mayo Clinic

    MTX: ≥ 15 mg/week subcutaneous (SC) or intramuscular (IM); ... At least one 4-week induction regimen of golimumab (200 mg SC at Week 0 and 100 mg SC at Week 2); ...

  3. Rectal Adenocarcinoma Clinical Trials

    This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC ...

  4. Meet Our Residents - General Surgery Residency (Florida) - Mayo Clinic College of Medicine & Science

    Jonathan Vandenberg, M.D.. Medical school: University of South Carolina. PGY-5. Class of 2027. Monica Mazur, M.D.. Monica Price, M.D.. Medical school: Rush ...

  5. Nonalcoholic Steatohepatitis Clinical Trials - Mayo Clinic Research

    ... (sc) to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) with no fibrosis to moderate fibrosis ...

  6. Michael B. Wallace, M.D. - Doctors and Medical Staff - Mayo Clinic

    He completed advanced endoscopic training at the Medical University of South Carolina under the mentor ship of Dr. ... South Carolina. 2001. MemberSearch ...

  7. Publications - Maria Alice V. Willrich, Ph.D. - Mayo Clinic

    ... SC, Sridharan M. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv. 2023 Feb ...

  8. Publications - Kevin C. Halling, M.D., Ph.D. - Mayo Clinic

    Gonzalez-Bosquet J, Shahi M, Yadav S, Kanwar N, Alvand S, Sosa C, Dowdy SC, Halling KC, Weroha SJ, Bakkum-Gamez JN, Podratz KC. ECPPF stratification ...

  9. Publications - Kah Whye Peng, Ph.D. - Mayo Clinic

    ... SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. IMMUNO-COV ... Concilio SC, Russell SJ, Peng KW. A brief review of reporter gene ...

  10. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    ... SC dose at Week 2 [or one 80 mg SC dose at Baseline, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]); OR; At ...